Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

Nakhoda, Shazia, Vistarop, Aldana, Wang, Y. Lynn·2023·British Journal of Haematology
DOI 10.1111/bjh.18418

Cited by (104)

Items 101–104 of 104

  1. Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms
    Shengchun Wang, Shilpa Rao, Cosimo Lobello, David Rushmore, Bhaumik Shah, Suzanne Paley, Pradeep Kumar Gupta, Andrew Kalgren, Dinesh Singh, Neil V. Sen et al. · 2026 · Leukemia
  2. Targeting cholesterol metabolism to overcome Zanubrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma
    Zhuojun Liu, Tianming Zhang, Ruonan Jia, Chenyue Wu, Fan Yang, Kai Hu, Wei Chen, Peng Cao, Zhe Yu, Jian Yu · 2026 · Medicine in Novel Technology and Devices
  3. PROTAC degraders for lymphoid malignancies — current status and future directions
    Anna Wolska, Tadeusz Robak · 2026 · Expert Opinion on Emerging Drugs
  4. BindingDB Entry 50022214: Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo.
    BindingDB · 2025 · UC San Diego